Document is current
Any future updates will be listed below
-
Authors
Grkovski, Milan https://orcid.org/0000-0001-7228-9497
Daras, Mariza
Bale, Tejus
Lyashchenko, Serge
Reiner, Anne S.
Mellinghoff, Ingo K.
Schöder, Heiko
Dunphy, Mark P. S. https://orcid.org/0000-0002-1886-1832
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (P30 CA008748)
- License Information
-
More Information
Article History
Received: 4 April 2025
Accepted: 6 July 2025
First Online: 26 September 2025
Declarations
:
: This study was approved by the Institutional Review Board (Protocol #16–078, ClinicalTrials.gov Identifier: NCT02617589) and performed under an investigational new drug application approved by U.S. Food and Drug Administration. The analysis was conducted following the principles outlined in the Declaration of Helsinki. Patient clinical information was collected anonymously from electronic medical records.
: All patients provided written informed consent.
: IKM reports receiving personal fees (advisory board services) from Agios, Black Diamond Therapeutics, Debiopharm Group, Erasca, Novartis, Prelude Therapeutics, Roche Therapeutics, Servier Pharmaceuticals, Voyager. IKM reports receiving grants from General Electric and Puma Biotechnology. No potential conflicts of interest relevant to this article exist.
